R&D – Talk Bio

FDA Rejects Biohaven’s Ataxia Drug Vyglxia, Forcing Company to Cut Costs After Second Approval Failure

2 days ago talkbio0Tagged Ataxia, Spinocerebellar, Biohaven, Clinical Trial Design, Drug Approval, external controls, IL31RA gene, In complete remission, R&D, Rejection, Troriluzole, United States Food and Drug Administration, Vyglxia

Biohaven; FDA rejection; Vyglxia; troriluzole; spinocerebellar ataxia; CRL (Complete Response Letter); clinical trial design; external controls; drug approval; R&D cuts

Pfizer Cuts 11 R&D Programs amid Ongoing Revenue Declines and Cost Realignment Efforts

3 days ago talkbio0Tagged Cost Savings, COVID19 (disease), digital enablement, earnings, Pfizer, Q3, R&D, Revenue Decline, Seagen acquisition

Pfizer; R&D cuts; revenue decline; cost savings; Q3 2025 earnings; COVID-19 product sales; digital enablement; AI in R&D; Seagen acquisition

Dr. Andreas Wallnöfer Named to Optigo Biotherapeutics Board of Directors

3 days ago talkbio0Tagged Andreas Wallnöfer, Biotechnology, board of directors, Dosage Forms, Drug Development, Hyaluronic Acid anchoring platform, IND-enabling studies, Ophthalmology specialty, Optigo Biotherapeutics, R&D, Retinal Diseases

Andreas Wallnöfer; Optigo Biotherapeutics; Board of Directors; ophthalmology; biotechnology; retinal diseases; IND-enabling studies; Hyaluronic Acid anchoring platform; pharmaceutical R&D; drug development

GSK Trims Pipeline and Upgrades Guidance in Emma Walmsley’s Last Earnings Report

1 week ago talkbio0Tagged dividend, earnings, Emma Walmsley, guidance upgrade, Medical Specialities, operating profit, pipeline reduction, R&D, SmithKline Beecham

GSK; pipeline reduction; earnings; Emma Walmsley; Q3 2025; guidance upgrade; Specialty Medicines; operating profit; dividend; R&D progress

Roche in Talks With US on Drug Pricing; Sets Out Pipeline and Dealmaking Ambitions

2 weeks ago talkbio0Tagged Benefit, dealmaking, direct-to-consumer sales, drug price, gene therapy, Government, Hemlibra, Investments, manager, Manufacturing, Ocrevus, Pharmaceutical Services, pipeline, R&D, Roche (company), U.S., Vabysmo

Roche; drug pricing; US government; pharmacy benefit managers; direct-to-consumer sales; pipeline; dealmaking; US investment; manufacturing; gene therapy; R&D; Ocrevus; Hemlibra; Vabysmo

Solventum Appoints Heather Knight as Chief Commercial Officer

2 weeks ago talkbio0Tagged Appointments, Chief Commercial Officer, Chris Barry, Dental Solutions, Global commercial operations, Health Information Systems, Heather Knight, Leadership, MedSurg, medtech, R&D, Solventum

Solventum; Heather Knight; Chief Commercial Officer; MedTech; Leadership appointment; Chris Barry; MedSurg; Dental Solutions; Health Information Systems; Global commercial operations; R&D

Takeda to Cut 137 Staffers After Exiting Cell Therapy Research

1 month ago talkbio0Tagged Cell Therapy, Exit, Industry, layoffs, Massachusetts (geographic location), pipeline shake-up, portfolio reprioritization, R&D, restructuring, strategic, Takeda

Takeda; layoffs; cell therapy exit; biotech industry; restructuring; Massachusetts R&D; strategic portfolio reprioritization; pipeline shake-up

A Concerning Pattern: Pharma Mulls UK Divestments as Government Action Lags in Life Sciences

2 months ago talkbio0Tagged AstraZeneca, Biological Science Disciplines, drug price, drug spending, eli lilly, Government, Investments, Merck, Nance-Horan syndrome, pharmaceutical divestment, Policy, R&D, sanofi, UK

UK life sciences; pharmaceutical divestment; Merck; AstraZeneca; Sanofi; Eli Lilly; R&D investment; drug pricing; government policy; NHS drug spending

GSK Commits $30 Billion to Bolster U.S. R&D and Manufacturing

2 months ago talkbio0Tagged Biopharma, Digital Technology, expansion, Investments, Manufacturing, R&D, SmithKline Beecham, supply chain, United States

GSK; $30 billion investment; U.S. expansion; R&D; manufacturing; biopharma; supply chain; advanced digital technologies

Gilead Unveils New Manufacturing Site in California as Part of $32B U.S. Investment Plan

2 months ago talkbio0Tagged Billion, Biological Factors, California, economic impact, expansion, Foster City, Gilead Sciences, Investments, Manufacturing, Manufacturing Facilities, R&D, Surgical construction, United States

Gilead Sciences; Foster City; California; manufacturing facility; biopharmaceuticals; $32 billion investment; economic impact; expansion; R&D; job creation; U.S. manufacturing